Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension – Insights from the SYMPLICITY HTN-3 trial

Circulation Journal

Volumn 80, Issue 6, 2016, Pages 1404-1412

  Kario, Kazuomi ^a   Bhatt, Deepak L ^b   Kandzari, David E ^c   Brar, Sandeep ^d   Flack, John M ^e   Gilbert, Colleen ^d   Oparil, Suzanne ^f   Robbins, Mark ^g   Townsend, Raymond R ^h   Bakris, George ⁱ  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PIEDMONT HEART INSTITUTE   (United States)

^d MEDTRONIC INC   (United States)

^e SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Obstructive sleep apnea; Renal denervation; Resistant hypertension; SYMPLICITY trial

Indexed keywords

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEMOGRAPHY; ELEVATED BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSITIVE END EXPIRATORY PRESSURE; RADIOFREQUENCY; RESISTANT HYPERTENSION; RISK FACTOR; SLEEP DISORDERED BREATHING; BLOOD PRESSURE; COMPLICATION; DENERVATION; DRUG RESISTANCE; HYPERTENSION; INNERVATION; KIDNEY; KIDNEY ARTERY; RANDOMIZED CONTROLLED TRIAL; SLEEP APNEA, OBSTRUCTIVE;

ADULT; AGED; BLOOD PRESSURE; DENERVATION; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; RENAL ARTERY; SLEEP APNEA, OBSTRUCTIVE;

EID: 84969642646     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0035     Document Type: Article

References (42)

1. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 136-143.
2. Monahan K, Redline S. Role of obstructive sleep apnea in cardiovascular disease. Curr Opin Cardiol 2011; 26: 541-547.
3. Goldsmith KA, Dyer MT, Schofield PM, Buxton MJ, Sharples LD. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual Life Outcomes 2009; 7: 96.
4. Floras JS. Sleep apnea and cardiovascular risk. J Cardiol 2014; 63: 3-8.
5. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study. JAMA 2000; 283: 1829-1836.
6. Muxfeldt ES, Margallo VS, Guimaraes GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens 2014; 27: 1069-1078.
7. Khan A, Patel NK, O'Hearn DJ, Khan S. Resistant hypertension and obstructive sleep apnea. Int J Hypertens 2013; 2013: 193010.
8. Walia HK, Li H, Rueschman M, Bhatt DL, Patel SR, Quan SF, et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med 2014; 10: 835-843.
9. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7: 677-685.
10. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: Implications for cardiac and vascular disease. JAMA 2003; 290: 1906-1914.
11. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-135.
12. Kario K. Obstructive sleep apnea syndrome and hypertension: Ambulatory blood pressure. Hypertens Res 2009; 32: 428-432.
13. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21: 2251-2257.
14. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622-629.
15. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752-1759.
16. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528-535.
17. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015; 65: 766-774.
18. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015; 385: 1957-1965.
19. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
20. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
21. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
22. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36: 219-227.
23. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: Results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014; 64: 1071-1078.
24. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23: 697-701.
25. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
26. Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: Implications for hypertension. J Hypertens 1997; 15: 1613-1619.
27. Usui K, Bradley TD, Spaak J, Ryan CM, Kubo T, Kaneko Y, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol 2005; 45: 2008-2011.
28. Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol (1985) 2006; 100: 343-348.
29. Hukins CA. Obstructive sleep apnea: Management update. Neuropsychiatr Dis Treat 2006; 2: 309-326.
30. Stepnowsky CJ, Dimsdale JE. Dose-response relationship between CPAP compliance and measures of sleep apnea severity. Sleep Med 2002; 3: 329-334.
31. Ding N, Lin W, Zhang XL, Ding WX, Gu B, Ni BQ, et al. Overnight fluid shifts in subjects with and without obstructive sleep apnea. J Thorac Dis 2014; 6: 1736-1741.
32. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565.
33. Shantha GP, Pancholy SB. Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea: A systematic review and meta-analysis. Sleep Breath 2015; 19: 29-34.
34. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 2012; 60: 172-178.
35. Kario K. Essential Manual of 24 Hour Blood Pressure Management: From Morning to Nocturnal Hypertension. Wiley-Blackwell, 2015; 1-138.
36. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
37. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015; 385: 1957-1965.
38. Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan: First randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J 2015; 79: 1222-1229.
39. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015; 65: 766-774.
40. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: A metaanalysis. J Hypertens 2004; 22: 435-445.
41. Warren RE, Marshall T, Padfield PL, Chrubasik S. Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract 2010; 60: 675-680.
42. Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, et al. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 2016; 171: 82-91.